MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, has opened an Asia-Pacific Bioprocessing Production Center in Daejeon, South Korea—a €300+ million investment, its largest Life Science spend in APAC. The 44,500‑m² facility expands the company’s bioprocessing production footprint in the region.
MilliporeSigma (Burlington, Mass.), the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the opening of a new Asia-Pacific Bioprocessing Production Center in Daejeon, South Korea. The center represents an investment of more than €300 million, the company’s largest Life Science investment in Asia-Pacific to date. The 44,500-square-meter site expands the […]
The post MilliporeSigma opens bioprocessing production center in Daejeon, South Korea appeared first on Chemical Engineering.
Login to comment
Login0 Replies
0 Replies
2 Replies
0 Replies
0 Replies
0 Replies
0 Replies
0 Replies
0 Replies
0 Replies
0 Replies
0 Replies
0 Replies
0 Replies
0 Replies